DEFINITIVE CONTRACT
Active75F40126C00096
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$1.5M
obligated · signed 6 days ago
EO-14398-A LONG-TERM VASCULAR MPS TO ASSESS CYCLIC CARDIOVASCULAR TOXICITY OF ONCOLOGY DRUGS
Performance timeline
Start
Sep 30, 2026
Current end
Sep 29, 2028
Potential end
Sep 29, 2030
with all options
Loading status
Estimated start: Sep 29, 2029
BRIGHAM & WOMENS HOSPITAL INC
Contract 75F40126C00096
UEI
QN6MS4VN7BD1
Parent Company
PARTNERS HEALTHCARE SYSTEM, INC
Capabilities & Certifications
Headquarters Location
Congressional District: 07
Current Obligation
$1,517,015
Base + Exercised Options
$2,998,734
Total Ceiling Value
$2,998,734
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
Place of Performance
Congressional District: 07
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.